prikaz prve stranice dokumenta The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
  Preuzmi
PDF 1.53 MB
Znanstveni rad - Izvorni znanstveni rad
The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
Diabetology & Metabolic Syndrome, 9 (2017); 97. https://doi.org/10.1186/s13098-017-0295-0
Božek, Tomislav; Blažeković, Antonela; Nikolac Perković, Matea; Gotovac Jerčić, Kristina; Šustar, Aleksandra; Smirčić-Duvnjak, Lea; Outeiro, Tiago F.; Pivac, Nela; Borovečki, Fran

Citirajte ovaj rad

Božek, T., Blažeković, A., Nikolac Perković, M., Gotovac Jerčić, K., Šustar, A., Smirčić Duvnjak, L. ... Borovečki, F. (2017). The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 9., 97. doi: 10.1186/s13098-017-0295-0

Božek, Tomislav, et al. "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus." Diabetology & Metabolic Syndrome, vol. 9, 2017, str. 97. https://doi.org/10.1186/s13098-017-0295-0

Božek, Tomislav, Antonela Blažeković, Matea Nikolac Perković, Kristina Gotovac Jerčić, Aleksandra Šustar, Lea Smirčić Duvnjak, Tiago F. Outeiro, Nela Pivac i Fran Borovečki. "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus." Diabetology & Metabolic Syndrome 9 (2017): 97. https://doi.org/10.1186/s13098-017-0295-0

Božek, T., et al. (2017) 'The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus', Diabetology & Metabolic Syndrome, 9, str. 97. doi: 10.1186/s13098-017-0295-0

Božek T, Blažeković A, Nikolac Perković M, Gotovac Jerčić K, Šustar A, Smirčić Duvnjak L, i sur.. The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome [Internet]. 04.12.2017. [pristupljeno 12.11.2024.];9:97. doi: 10.1186/s13098-017-0295-0

T. Božek, et al., "The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus", Diabetology & Metabolic Syndrome, vol. 9, str. 97, Prosinac 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:450360. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:450360
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
AutorTomislav Božek
AutorAntonela Blažeković
AutorMatea Nikolac Perković
AutorKristina Gotovac Jerčić
AutorAleksandra Šustar
AutorLea Smirčić-Duvnjak
AutorTiago F. Outeiro
AutorNela Pivac
AutorFran Borovečki
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background: Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long-acting insulin with a weight sparing effect. The aim of this study was to determine the association of catechol O-methyltransferase (COMT) Val108/158Met and dopamine-beta-hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52-week observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood samples, genotyping of DBH-1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) was performed. ----- Results: Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH-1021C/T genotypes and weight and/or glucose control was detected in diabetes patients or in healthy control subjects. ----- Conclusions: This study showed that the presence of one or two A allele of the COMT Val108/158Met was associated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II diabetes, separating them as best candidates for detemir therapy.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology & Metabolic Syndrome
Brojčani podacivol. 9, str. 97
p-ISSN1758-5996
DOIhttps://doi.org/10.1186/s13098-017-0295-0
URN:NBNurn:nbn:hr:105:450360
Datum objave publikacije2017-12-04
URL dokumentahttps://doi.org/10.1186/s13098-017-0295-0
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:04:43